IXHL
Incannex Healthcare Limited - ADR

11,332
Loading...
Loading...
News
all
press releases
Incannex Healthcare Stock Sees Retail Chatter Explode 234% Over Last Week
The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.
Stocktwits·6d ago
News Placeholder
More News
News Placeholder
Why Is Incannex Healthcare Stock Surging Today?
The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.
Stocktwits·1mo ago
News Placeholder
This Pharma Stock Soared 23% Today But Is Still Down Over 70% In 2025 – Find Out More
The company’s CEO said that the current market valuation does not accurately reflect the significant progress the firm has made across its clinical programs.
Stocktwits·1mo ago
News Placeholder
Incannex Surges 720% On Sleep Apnea Trial Progress: ‘Penny Bio Pharma Mania’ Lifts Retail Sentiment
The company completed patient dosing in its Phase 2/3 trial for IHL-42X, a once-daily oral treatment for obstructive sleep apnea. Retail enthusiasm surged as the company eyes FDA talks, Phase 3 rollout in the U.S., and early commercial interest.
Stocktwits·5mo ago
News Placeholder
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies. read more...
Benzinga·1y ago
News Placeholder
FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder
Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug...
Benzinga·1y ago
News Placeholder
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Up 113.1% in March
Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 208,200...
Ticker Report·1y ago
News Placeholder
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
Appendix: Comparison of PsiGAD Treatments to Existing Registered Treatments for Anxiety Figure: meta-analysis(1) of psychotropic medications for GAD, as measured by the HAM-A; the best...
Globe Newswire·2y ago
News Placeholder
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology...
Globe Newswire·2y ago
News Placeholder
Is Incannex Healthcare (NASDAQ:IXHL) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St·2y ago

Latest IXHL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.